Manejo perioperatorio de la cirugía de citorreducción con quimioterapia intraperitoneal hipertérmica
PDF
HTML

Palabras clave

Quimioterapia intraperitoneal hipertónica
Citorreducción
Carcinomatosis peritoneal
Monitoreo hemodinámico

Cómo citar

1.
Videla C, Di Stefano S. Manejo perioperatorio de la cirugía de citorreducción con quimioterapia intraperitoneal hipertérmica. Rev Arg de Ter Int. [Internet]. 20 de enero de 2021 [citado 25 de octubre de 2021];38:e708.16092020. Disponible en: //revista.sati.org.ar/index.php/MI/article/view/708

Resumen

Se define a la carcinomatosis peritoneal como la diseminación tumoral dentro de la cavidad abdominal secundaria al crecimiento de los tumores de la superficie peritoneal o de órganos viscerales. Esta condición, independientemente del origen del tumor primario, suele estar asociada con la progresión de la enfermedad oncológica de base y lleva aparejado un peor pronóstico a corto plazo. En los últimos años, la mejor comprensión de las vías de diseminación tumoral asociada con la función protectora de la barrera del peritoneo contra la diseminación cancerígena, ha hecho que la carcinomatosis peritoneal sea considerada una enfermedad locorregional. En consecuencia, han surgido nuevas estrategias terapéuticas que combinan la cirugía de citorreducción con la quimioterapia intraperitoneal hipertérmica en pacientes que sufren carcinomatosis peritoneal secundaria a tumores de origen apendicular, gastrointestinal, ginecológico y a mesotelioma peritoneal, con resultados prometedores en cuanto a la prolongación de la supervivencia.El objetivo de esta monografía es hacer una revisión bibliográfica del manejo perioperatorio de los pacientes que se someten a una cirugía de citorreducción asociada a quimioterapia intraperitoneal hipertérmica y explicar los fundamentos fisiológicos con las posibles complicaciones de este procedimiento asociadas a los cambios hemodinámicos, respiratorios y metabólicos.
PDF
HTML

Citas

1. Coccolini F., Gheza F., Lotti M., et al. - “Peritoneal carcinomatosis.” World J Gastroenterol. 2013 Nov 7; 19 (41): 6979–6994.
2. Sugarbaker PH. “Peritonectomy procedures.” Ann Surg 1995; 221: 29-42.
3. Rothfield, Kenneth P., Crowley K. “Anesthesia Considerations during Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.” Surgical Oncology Clinics of North America. 2012. 21 (4): 533–41.
4. Jafari, Mehraneh D., Halabi W., et al. “Surgical Outcomes of Hyperthermic Intraperitoneal Chemotherapy: Analysis of the American College of Surgeons National Surgical Quality Improvement Program.” JAMA Surgery. 2014. 149 (2): 170–75.
5. Padmakumar A. “Intensive Care Management of Patient After Cytoreductive Surgery and HIPEC - A Concise Review.” Indian Journal of Surgical Oncology. 2016. 7 (2): 244–48.
6. Elias D., Gilly F., Boutitie F., et al. “Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French Study” J Clin Oncol. 2010. 28 (1):63-68.
7. Yan T., Black D, Savady R, Sugarbaker P. “ Systematic Review on the Efficacy of Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis From Colorectal Carcinoma” J Clin Oncol. 2006. 24: 4011-4019.
8. Sugarbaker P. “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: Progress toward a new standard of care” Cancer Treat Rev. 2016 Jul;48:42-9.
9. Wright A., Cronin A., Milne D., et al. “Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer” J Clin Oncol. 2015 Sep 10;33(26):2841-7.
10. Yan T., Black D., Savady R., Sugarbaker P. “A Systematic Review on the Efficacy of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei” Annals of Surgical Oncology. 2007. 14(2):484–492.
11. Yan T., Welch L., Black D., Sugarbaker P. “A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma” Annals of Oncology. 2007. 18: 827–834.
12. Königsrainer I., Beckert S. “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Where are we?” World J Gastroenterol 2012; 18(38): 5317-5320.
13. Glehen O., Cotte E., Kusumara S., et al. “Hyperthermic Intraperitoneal Chemotherapy: Nomenclature and Modalities of Perfusion” Journal of Surgical Oncology 2008; 98: 242–246.
14. Bree E. “Optimal drugs for HIPEC in different tumors” JBUON 2015; 20 (Suppl. 1): S40-S46.
15. Lemoine L., Sugarbaker P., Van der Speeten K. “Drugs, doses, and durations of intraperitoneal chemotherapy: standardizing HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma.” International Journal of Hyperthermia, 2017. 33(5):1-34
16. Brucher B., Piso P., Verwaal V., et al “Peritoneal Carcinomatosis: Cytoreductive Surgery and HIPEC -Overview and Basics” Cancer Investigation 2012, 30:209–224
17. Esquivel J., Angulo F., Bland R., Stephens A., Sugarbaker “Hemodynamic and Cardiac Function Parameters During Heated Intraoperative Intraperitoneal Chemotherapy Using the Open “Coliseum Technique” Annals of Surgical Oncology, 2000. 7(4):296–300
18. Colantonio L., Claroni C., Fabrizi L., et al. ¨A Randomized Trial of Goal Directed vs Standard Fluid Therapy in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy” J Gastrointest Surg. 2015, 19:722–729.
19. Schulermann C., Hoeppner J., Benk C., Schmidt R., Loop T., Kalbhenn J.”Intra-abdominal pressure, Cardiac Index and vascular resistance during hyperthermic intraperitoneal chemotherapy: a prospective observational study “ Minerva Anestesiologica 2016 February; 82 (2):160-9.
20. Raspe C., Flother L., Schneider R., Bucher M., Piso P. “Best practice for perioperative management of patients with cytoreductive surgery and HIPEC” EJSO. 2017, (43) 1013 - 1027.
21. Pret V.i, Chang D., Sugarbaker P. “Pulmonary Complications following Cytoreductive Surgery and Perioperative Chemotherapy in 147 Consecutive Patients” Gastroenterology Research and Practice. 2012, Article ID 635314.
22. Ferreyra, G. et al. “Continuous positive airway pressure for treatment of respiratory complications after abdominal surgery: a systematic review and meta-analysis. “ Ann. Surg. 2008. 247, 617–626.
23. Arakelian E, Gunningberg L, Larsson J, Norlén K, Mahteme H.” Factors influencing early postoperative recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.” Eur J Surg Oncol. 2011 Oct; 37(10):897-903.
24. Ljungqvist O., Scott M., Fearon K.. “Enhanced Recovery After Surgery. A Review” JAMA Surg. 2017;152(3):292-298.
25. Osseis M., Weyrech J., Gayat E., et al. “Epidural analgesia combined with a comprehensive physiotherapy program after Cytoreductive Surgery and HIPEC is associated with enhanced post-operative recovery and reduces intensive care unit stay: A retrospective study of 124 patients” EJSO. 2016 (42) 1938 - 1942.
26. Vashi P., Gupta D., Lammersfeld C., et al.. “The relationship between baseline nutritional status with subsequent parenteral nutrition and clinical outcomes in cancer patients undergoing hyperthermic intraperitoneal chemotherapy” Nutrition Journal 2013, 12:118
Singer P., Blaser A., Berger M et al. “ESPEN guideline on clinical nutrition in the intensive care unit” Clinical Nu
Creative Commons License
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-CompartirIgual 4.0.

Derechos de autor 2021 Revista Argentina de Terapia Intensiva